Pliant Therapeutics Inc (NAS:PLRX)
$ 13.29 -0.11 (-0.82%) Market Cap: 801.73 Mil Enterprise Value: 380.63 Mil PE Ratio: 0 PB Ratio: 1.83 GF Score: 36/100

Pliant Therapeutics Inc INTEGRIS-IPF Call Transcript

May 01, 2023 / 12:00PM GMT
Release Date Price: $22.31 (-21.03%)
Operator

Good morning, and thank you for joining Pliant Therapeutics' Conference Call. (Operator Instructions). Please be advised that today's conference is being recorded. I would like to turn the call over to Christopher Keenan, Pliant Therapeutics' Vice President and Investor Relations. Mr. Keenan?

Christopher Keenan
Pliant Therapeutics, Inc. - VP, IR and Corporate Communications

Thank you, Shannon, and good morning, everyone. Thank you for joining us for Pliant's presentation of 24-week data from the INTEGRIS-IPF trial, our Phase 2 clinical trial evaluating Bexotegrast, formerly PLN74809, at 320 milligrams in patients with idiopathic pulmonary fibrosis. Yesterday, we issued a press release that will be referenced during this call and is available under the Investor and Media section of our corporate website. The slides accompanying today's webcast are also available in the same section.

During today's call, we will be making forward-looking statements, including those related to the therapeutic potential of Bexotegrast and our plans for the future

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot